Novartis Ends $2.2 Billion Global PD-1 Partnership with BeiGene
publication date: Sep 19, 2023
Once again, a big pharma has returned partnership rights for BeiGene’s anti-PD-1 candidate to the China company. This time it was Novartis who backed out of a $2.2 billion deal for ex-China rights to tislelizumab. Novartis claimed that regulatory issues for the drug caused the change in plans. Ironically, BeiGene also announced that the EU has approved tislelizumab as a second-line monotherapy for esophageal squamous cell carcinoma. Novartis paid $650 million upfront for the rights, plus up to $1.3 billion in regulatory milestones. Previously, Bristol Myers Squibb returned tislelizumab to BeiGene after making a $650 million upfront payment. More details....
Stock Symbols: (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) (NYSE: NVS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.